Evidence map›Paper›PMID 38111035›Full record

ArticleJournal of nanobiotechnology2023

Rational design of NIR-II molecule-engineered nanoplatform for preoperative downstaging and imaging-guided surgery of orthotopic hepatic tumor.

Qi Pan, Ke Li, Xueqin Kang, Kaixuan Li, Zihe Cheng, Yafei Wang, Yuye Xu, Lei Li, Na Li, Guilong Wu and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Qi PanCenter for Molecular lmaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research lnstitute, University of South China, Hengyang, 421001, China.
Ke LiXi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, 710021, China.
Xueqin KangSchool of Life Science and Technology, Engineering Research Center of Molecular & Neuro Imaging of the Ministry of Education, Xidian University, Xi'an, 710126, China.
Kaixuan LiMedical Imaging Department, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, 710038, China.
Zihe ChengXi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, 710021, China.
Yafei WangXi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, 710021, China.
Yuye XuXi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, 710021, China.
Lei LiRadiology Department, Ninth Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, 710054, China.
Na LiCenter for Molecular lmaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research lnstitute, University of South China, Hengyang, 421001, China.
Guilong WuCenter for Molecular lmaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research lnstitute, University of South China, Hengyang, 421001, China.
Sha YangCenter for Molecular lmaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research lnstitute, University of South China, Hengyang, 421001, China.
Shuo QiDepartment of Hepatopancreatobiliary Surgery, Hengyang Medical School, The First Affiliated Hospital, University of South China, Hengyang, 421001, Hunan, China.
Guodong ChenDepartment of Hepatopancreatobiliary Surgery, Hengyang Medical School, The First Affiliated Hospital, University of South China, Hengyang, 421001, Hunan, China.
Xiaofeng TanCenter for Molecular lmaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research lnstitute, University of South China, Hengyang, 421001, China. tanxiaofeng@usc.edu.cn.
Yonghua ZhanSchool of Life Science and Technology, Engineering Research Center of Molecular & Neuro Imaging of the Ministry of Education, Xidian University, Xi'an, 710126, China. yhzhan@xidian.edu.cn.
Li TangCenter for Molecular lmaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research lnstitute, University of South China, Hengyang, 421001, China. tanglicq@outlook.com.
Wenhua ZhanDepartment of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, 750004, China. zhanwhgood@163.com.
Qinglai YangCenter for Molecular lmaging Probe, Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Hengyang Medical School, Cancer Research lnstitute, University of South China, Hengyang, 421001, China. qingyu513@126.com.
University of South China · CNXi'an Medical University · CNXidian University · CNNingxia Medical University · CNXi'an Jiaotong University · CN

Funding

Health Commission of Ningxia Hui Autonomous Region Science and Technology Support Project for Quality Development of Medical Institutions 2023-NWKYT-019Hospital fund of the Second Affiliated Hospital of Xi'an Medical University 22KY0105Natural Science Basic Research Key Program of Shaanxi Province Program No. 2023-JC-ZD-53Science and Technology Innovation Platform of Shaanxi Key Laboratory of Brain Disorders, Xi'an Medical University 20NBZD01Shaanxi Provincial Education Department Service for Local Scientific Research Program 22JC056Shaanxi Social Development Science and Technology Plan 2021SF-271the Key Research and Development Program in Ningxia Province of China 2022BEG03080the Key Research and Development Program of Hunan Province,China 2022SK2053the National Natural Science Foundation of China 22374065the National Natural Science Foundation of China 82260473the Natural Science Foundation of Hunan Province of China 2022JJ40361the Science and Technology Innovation Program of Hunan Province "Huxiang Young Talents Plan" 2021RC3106
6 · The paper itself

Abstract

Orthotopic advanced hepatic tumor resection without precise location and preoperative downstaging may cause clinical postoperative recurrence and metastasis. Early accurate monitoring and tumor size reduction based on the multifunctional diagnostic-therapeutic integration platform could improve real-time imaging-guided resection efficacy. Here, a Near-Infrared II/Photoacoustic Imaging/Magnetic Resonance Imaging (NIR-II/PAI/MRI) organic nanoplatform IRFEP-FA-DOTA-Gd (IFDG) is developed for integrated diagnosis and treatment of orthotopic hepatic tumor. The IFDG is designed rationally based on the core "S-D-A-D-S" NIR-II probe IRFEP modified with folic acid (FA) for active tumor targeting and Gd-DOTA agent for MR imaging. The IFDG exhibits several advantages, including efficient tumor tissue accumulation, good tumor margin imaging effect, and excellent photothermal conversion effect. Therefore, the IFDG could realize accurate long-term monitoring and photothermal therapy non-invasively of the hepatic tumor to reduce its size. Next, the complete resection of the hepatic tumor in situ lesions could be realized by the intraoperative real-time NIR-II imaging guidance. Notably, the preoperative downstaging strategy is confirmed to lower the postoperative recurrence rate of the liver cancer patients under middle and advanced stage effectively with fewer side effects. Overall, the designed nanoplatform demonstrates great potential as a diagnostic-therapeutic integration platform for precise imaging-guided surgical navigation of orthotopic hepatic tumors with a low recurrence rate after surgery, providing a paradigm for diagnosing and treating the advanced tumors in the future clinical translation application.

Indexed as

Liver NeoplasmsNanoparticlesSurgery, Computer-AssistedCell Line, TumorHumansMagnetic Resonance ImagingPhototherapyDownstagingHepatic tumorImaging guidancePhotothermal therapySurgical resection

Identifiers

PMID38111035
PMCPMC10726515
OpenAlexW4389861986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.